The Filing Desk

EDAP TMS

FOCL · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

FOCL · Last close · November 19, 2026
$2.82
Value EDAP TMS yourself

EDAP TMS's revenue rose 1.6% to $70 million in fiscal 2025. Its operating margin was −35.0%, down from −32.0% a year earlier. The diluted share count rose 0.4%.

EDAP TMS SA Latest fiscal year ended December 31, 2025 10-K filed March 25, 2026 · 0001104659-26-034528 Updated
Revenue
$70M
1.6%
Operating margin
−35.0%
3.0 pts
Net income
−$29M
 
Free cash flow
—
 
Return on capital
−83.4%
 
Market cap
$120M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

What EDAP TMS does

EDAP TMS is a French medical device company, founded in 1979 and based in Vaulx-en-Velin, that trades under the name Focal One. It makes machines that use high-intensity focused ultrasound, or HIFU, to destroy diseased tissue without cutting into the body. Its main product, the Focal One robotic HIFU system, lets urologists treat targeted areas of the prostate in men with prostate cancer while limiting harm to nearby tissue. It sells to hospitals and clinics in the United States, Europe, Asia and elsewhere.

It earns money from selling the machines and from the recurring sale of disposable parts used in each treatment and of maintenance services. The company has shifted its focus to HIFU and away from older lines, such as lithotripsy machines that break up kidney stones and other companies' urology products it distributes; it still sells and services these in some markets. It sells through its own teams and through distributors abroad.

Focal One has been cleared for prostate tissue treatment in the US since 2018 and in Europe since 2013. The company is running studies to use it for an enlarged prostate and for endometriosis, a painful condition in women; for the latter it has a European approval and an FDA Breakthrough Device designation. It makes its products at a single site in France.

Its biggest risks, as it describes them

  • Doctors may not widely adopt HIFU, which may never become a standard treatment.
  • Needing new financing, which may not be available when required.
  • Health authorities and insurers may not pay for procedures using its products.
  • Its clinical trials for new uses may fail or not lead to approval.
  • Its dependence on a single manufacturing site and a few suppliers.
From EDAP TMS's annual report on Form 10-K, filed March 25, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both. Where the filings' structured data doesn't give a year's net income, the column is blank.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

EDAP TMS lost money in fiscal 2025: a net loss of $29 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments——483120
Debt incl. finance leases———1224
Net debt (negative means net cash)———−194
Net debt to EBITDA—————
Debt to equity———0.3x1.3x
Interest coverage———−86.8x−31.3x
Current ratio———1.9x1.5x
Quick ratio———1.4x1.2x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Free cash flow is cash from operations minus capital expenditure. The SEC's structured data for EDAP TMS's filings doesn't give both for any year, so free cash flow is left out.

Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project EDAP TMS's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What EDAP TMS says to expect

  • Full year 2026: revenueWe are narrowing our full-year 2026 revenue guidance to be in the range of $50.0 to $52.0 million, representing 34% to 39% growth over 2025, from the prior range of $50.0 to $54.0 million.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 5, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 4 insiders bought $450,700 of EDAP TMS shares on the open market, and none sold any.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Aug 14, 2026Lance WillseyDirectorBought50,000$4.75$237,500Form 4
Aug 14, 2026Ryan RhodesChief Executive Officer, DirectorBought21,000$4.75$99,750Form 4
Aug 14, 2026Joshua LevineDirectorBought10,000$4.75$47,500Form 4
Aug 14, 2026Steven AnnenSVP, Marketing & Product Mgmt.Bought5,000$4.75$23,750Form 4
May 11, 2026Joshua LevineDirectorBought10,000$4.22$42,200Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40———
Altman Z''—−1.90−5.40
Accruals ratio——−15.2%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positive——Fail
Cash from operations is positive—FailFail
Return on assets rose———
Cash from operations exceeds net income—PassPass
Debt fell relative to assets———
Current ratio rose——Fail
Share count didn't riseFailFailFail
Gross margin rose——Pass
Revenue rose relative to assets———
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put EDAP TMS side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
EDAP TMSFY251.6%−35.0%—−83.4%——
AVITA MedicalFY2511.4%−59.4%−45.0%−354.1%—2Compare
ElectromedFY2615.3%18.8%11.4%———Compare
Sight SciencesFY25−3.1%−48.0%−38.7%——5Compare
Pro DexFY2616.4%16.8%8.7%19.6%0.6x7Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue————————6970
Revenue growth—————————1.6%
Gross profit————————2930
Research and development————————810
Operating income————————−22−25
Net income————————−21−29
Diluted EPS (US$)————————−0.55−0.78
Diluted shares (millions)29292930293234373737
Cash flow
Cash from operations————————−15−16
Capital expenditure——————————
Free cash flow——————————
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation——————————
Balance sheet at fiscal year end
Cash and short-term investments———————483120
Debt incl. finance leases————————1224
Total assets————————8979
Total liabilities————————4760
Shareholders' equity———————634219
Margins and ratios
Gross margin————————41.4%42.5%
Operating margin————————−32.0%−35.0%
Net margin————————−29.7%−41.5%
Free cash flow margin——————————
Rule of 40 (growth + FCF margin)——————————
Return on capital—————————−83.4%
Return on equity—————————−94.5%
Return on assets—————————−34.7%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: EDAP TMS's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with EDAP TMS.